



Biological Safety Evaluation

Using a risk-based approach to safety



Safeguarding Global Health[™]
– with every test we complete.

www.nelsonlabs.com

Instead, manufacturers of modern-day, complex devices need to assess the biocompatibility of their medical device materials and processes by taking a holistic risk-based approach to their biological safety evaluations.

Our experts have broken out the biological safety evaluation process into three distinct phases that can be used to accommodate a medical device in any stage of the product lifecycle.

This process is comprehensive and available today:

STEP 1: IDENTIFY RISK
Biological Evaluation Plan (BEP)

STEP 2: MITIGATE RISK THROUGH TESTING
Biological Evaluation

STEP 3: EVALUATE THE RESULTS
Biological Evaluation Report (BER)

Medical device manufacturers
benefit from the **outside perspective**
of the experts at Nelson Labs through
the **biological evaluation process.**

STEP 1: IDENTIFY RISK
Biological Evaluation Plan (BEP)

Create a **Biological Evaluation Plan (BEP)**; consider the device materials, intended use, and existing data to prescribe a risk-based approach to the evaluation of device safety. Risks are identified considering patient contact and duration, materials, processing and their potential to cause harm.

What should be included in a BEP?

Physical / Material Information

- Suppliers
- Patient contact
- Specification sheets
- Testing information on raw materials

Special Test Sample Preparations

- Master product
- Absorption capacity
- Parts to include or exclude
- Cut/don't cut

Device Description & Categorization

(based on ISO 10993-1)

- Clinical use
- Duration of exposure (including cumulative)
- Include pictures

Outline Applicable Testing & Risk Assessments

- Tests to perform based on risk to patient
- Conversation of areas where there is no risk (important if FDA asks for consideration in a particular area that does not apply to your specific device.)

Standards


ISO 10993-1:2018: “Biological Evaluation of Medical Devices Part 1: Evaluation and testing within a risk management process.”

US FDA guidance document “Use of International Standard ISO 10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation and testing within a risk management process.’”

MDR Regulation (EU) 2017/45 of the European Parliament and of the Council of 5 April 2017 on Medical Devices

STEP 2: MITIGATE RISK THROUGH TESTING
Biological Evaluation

Execute the Biological Evaluation: based on the risks identified in the BEP, perform a combination of analytical chemistry testing, biocompatibility testing and assessment, and/or toxicological risk assessment.



STEP 3: EVALUATE THE RESULTS
Biological Evaluation Report (BER)

Biological Evaluation Report (BER); written by Nelson Labs’ experts, this information is a summary of all the evidence gathered to support the biological safety of the device and acts as a conclusion statement to the entire project.

Anatomy of a BER:

- A.** Summary of the device, its intended use, and the strategy used to evaluate the potential biological risks associated with the device
- B.** Review of the outcome
 - Biocompatibility tests
 - Chemistry testing w/tox assessment
 - Risks addressed purely by material and literature review
- C.** Discussion and explanation of unexpected results or material/processing changes conclusion
 - If there are tests which did not pass, a discussion of the relationship between the failure and actual safety of a device;
 - An assessment of the impact raw materials/manufacturing changes might have on the device (when a part of the device/manufacturing process changes from what was tested to the device that is being submitted).
- D.** Overall conclusion on device biological safety
 - Conclusion statement that the device has been evaluated and complies with ISO 10993 standards
 - Signed by an expert with the appropriate education and experience to make the final conclusion based on all data and evidence provided (as required in ISO 10993-1).

Unique Compound Screener Database

Nelson Labs exclusively owns the most expansive library of 5000 medical device compounds in the world - including approximately 2000 specific non-volatiles. This tool reduces the reliance on animal testing, saving manufacturers time and money when utilized during the Biological Safety Evaluation.